Exact Sciences said on Monday that it will present data supporting the positive impact of its Cologuard molecular colorectal cancer screening tool during the American College of Gastroenterology (ACG) Annual Meeting, being held October 21-26.
For the first time, Exact Sciences data will be given showing details of the positive impacts for patients when costs associated with follow-up colonoscopy are eliminated after a positive stool-based test, the firm said.
The data will also provide details about the value of Cologuard in detecting serrated polyps, and the importance of reconsidering the definition of false positive outcomes from stool tests in CRC screening, Exact Sciences added.
"These results provide key information to help screen more people for colorectal cancer and support the use of Cologuard as an FDA-approved, noninvasive screening option that is included in U.S. Preventive Services Task Force guidelines," Dr. Paul Limburg, chief medical officer, screening, at Exact Sciences, said in a statement.
